Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo C49 English + 你好 (nǐ hǎo) = limitless possibilities. Start learning Mandarin Chinese today—for free, forever. Amedeo C49 is completely free, for life. Next week: +49.

Influenza

Free Subscription Articles published in Antimicrob Agents Chemother Retrieve available abstracts of 36 articles: HTML format

Single Articles

September 2025
1. WU Q, Lv L, Yan S, Wang Y, et al
   A first-in-human phase I study to evaluate the safety, tolerability, and pharmacokinetics of a novel anti-influenza agent suraxavir marboxil in healthy Chinese subjects.
   Antimicrob Agents Chemother. 2025 Sep 30:e0068525. doi: 10.1128/aac.00685.
   PubMed     Abstract available
   
   
   August 2025
2. ZHOU Y, Meng X, Li J, Zeng G, et al
   Safety, tolerability, and pharmacokinetics of anti-SARS-CoV-2 monoclonal antibody SA55 injection in healthy participants.
   Antimicrob Agents Chemother. 2025;69:e0056825.
   PubMed     Abstract available
   
   
   
3. TATE M, Illingworth CJR, MacGregor G, Cunningham L, et al
   Clinical effectiveness, safety, and viral mutagenicity of oral favipiravir for COVID-19: results from a community-based, open-label, randomized Phase III trial.
   Antimicrob Agents Chemother. 2025;69:e0005425.
   PubMed     Abstract available
   
   
   
4. HARFOOT R, Lawley B, Hernandez LC, Kuang J, et al
   Synthetic host defense peptide inhibits SARS-CoV-2 replication in vitro.
   Antimicrob Agents Chemother. 2025;69:e0170024.
   PubMed     Abstract available
   
   
   
5. GOMI S, Price E, Burgoyne H, Faozia S, et al
   Omadacycline exhibits anti-inflammatory properties and improves survival in a murine model of post-influenza MRSA pneumonia.
   Antimicrob Agents Chemother. 2025 Aug 4:e0046925. doi: 10.1128/aac.00469.
   PubMed     Abstract available
   
   
   July 2025
6. YAMADA AY, de Souza AR, Madalosso G, de Assis DB, et al
   Emergence of carbapenem-resistant Acinetobacter baumannii clonal complex 2 in multiple hospitals in Sao Paulo state, Brazil.
   Antimicrob Agents Chemother. 2025 Jul 23:e0186524. doi: 10.1128/aac.01865.
   PubMed     Abstract available
   
   
   June 2025
7. MENG X, Zhang C, Wang X, Shi J, et al
   A branched peptide targets virus and host to block influenza virus and rhinovirus entry.
   Antimicrob Agents Chemother. 2025 Jun 25:e0002425. doi: 10.1128/aac.00024.
   PubMed     Abstract available
   
   
   April 2025
8. PANG Y, Li H, Chen X, Cao Y, et al
   A phase I, single-center, randomized, open-label, three-period crossover study to evaluate the drug-drug interaction between ZSP1273 and oseltamivir in healthy Chinese subjects.
   Antimicrob Agents Chemother. 2025;69:e0172924.
   PubMed     Abstract available
   
   
   March 2025
9. ZHAO L, Li C, Wang M, Zhou M, et al
   Potent antiviral activity of simnotrelvir against key epidemic SARS-CoV-2 variants with a high resistance barrier.
   Antimicrob Agents Chemother. 2025 Mar 10:e0155624. doi: 10.1128/aac.01556.
   PubMed     Abstract available
   
   
   February 2025
10. RODRIGUEZ L, Lee HW, Li J, Martin R, et al
    SARS-CoV-2 resistance analyses from the Phase 3 PINETREE study of remdesivir treatment in nonhospitalized participants.
    Antimicrob Agents Chemother. 2025;69:e0123824.
    PubMed     Abstract available
    
    
    December 2024
11. MENDES S, Guimaraes LC, Costa PAC, Fernandez CC, et al
    Intranasal liposomal angiotensin-(1-7) administration reduces inflammation and viral load in the lungs during SARS-CoV-2 infection in K18-hACE2 transgenic mice.
    Antimicrob Agents Chemother. 2024;68:e0083524.
    PubMed     Abstract available
    
    
    November 2024
12. ZHANG M, Lian X, Gao Y, Jiang L, et al
    LDC000067, a CDK9 inhibitor, unveils promising results in suppressing influenza virus infections in vitro and in vivo.
    Antimicrob Agents Chemother. 2024 Nov 20:e0117224. doi: 10.1128/aac.01172.
    PubMed     Abstract available
    
    
    October 2024
13. CARLIN AF, Beadle JR, Ardanuy J, Clark AE, et al
    Oral pharmacokinetics and efficacy of oral phospholipid remdesivir nucleoside prodrugs against SARS-CoV-2 in mice.
    Antimicrob Agents Chemother. 2024;68:e0103924.
    PubMed     Abstract available
    
    
    
14. MIYASHITA N, Nakamori Y, Ogata M, Fukuda N, et al
    Efficacy of ensitrelvir for cough due to COVID-19 Omicron variant in medical healthcare workers.
    Antimicrob Agents Chemother. 2024;68:e0106424.
    PubMed     Abstract available
    
    
    September 2024
15. FAGHIHI I, Yan VC
    Clinical pharmacodynamics of obeldesivir versus remdesivir.
    Antimicrob Agents Chemother. 2024;68:e0096924.
    PubMed    
    
    
    
16. POLI ANR, Tietjen I, Nandwana NK, Cassel J, et al
    Design of novel and highly selective SARS-CoV-2 main protease inhibitors.
    Antimicrob Agents Chemother. 2024 Sep 3:e0056224. doi: 10.1128/aac.00562.
    PubMed     Abstract available
    
    
    August 2024
17. FAGHIHI I, Yan VC
    Remdesivir treatment does not reduce viral titers in patients with COVID-19.
    Antimicrob Agents Chemother. 2024;68:e0085624.
    PubMed     Abstract available
    
    
    
18. SALOMEZ-IHL C, Giai J, Barbado M, Paris A, et al
    H(2) inhalation therapy in patients with moderate COVID-19 (H(2)COVID): a prospective ascending-dose phase I clinical trial.
    Antimicrob Agents Chemother. 2024;68:e0057324.
    PubMed     Abstract available
    
    
    June 2024
19. SHIN JS, Jang Y, Kim D-S, Jung E, et al
    Inhibition of endocytic uptake of severe acute respiratory syndrome coronavirus 2 and endo-lysosomal acidification by diphenoxylate.
    Antimicrob Agents Chemother. 2024;68:e0034124.
    PubMed     Abstract available
    
    
    May 2024
20. CLEGG LE, Stepanov O, Schmidt H, Tang W, et al
    Accelerating therapeutics development during a pandemic: population pharmacokinetics of the long-acting antibody combination AZD7442 (tixagevimab/cilgavimab) in the prophylaxis and treatment of COVID-19.
    Antimicrob Agents Chemother. 2024;68:e0158723.
    PubMed     Abstract available
    
    
    April 2024
21. CHESNOKOV A, Ivashchenko AA, Matsuzaki Y, Takashita E, et al
    Influenza C virus susceptibility to antivirals with different mechanisms of action.
    Antimicrob Agents Chemother. 2024 Apr 8:e0172723. doi: 10.1128/aac.01727.
    PubMed     Abstract available
    
    
    
22. XU S, Esmaeili S, Cardozo-Ojeda EF, Goyal A, et al
    Two-way pharmacodynamic modeling of drug combinations and its application to pairs of repurposed Ebola and SARS-CoV-2 agents.
    Antimicrob Agents Chemother. 2024;68:e0101523.
    PubMed     Abstract available
    
    
    
23. TANG W-F, Chang Y-H, Lin C-C, Jheng J-R, et al
    BPR3P0128, a non-nucleoside RNA-dependent RNA polymerase inhibitor, inhibits SARS-CoV-2 variants of concern and exerts synergistic antiviral activity in combination with remdesivir.
    Antimicrob Agents Chemother. 2024;68:e0095623.
    PubMed     Abstract available
    
    
    March 2024
24. YU Y, Chen S, Zhang H, Duan Y, et al
    A panel of janus kinase inhibitors identified with anti-inflammatory effects protect mice from lethal influenza virus infection.
    Antimicrob Agents Chemother. 2024 Mar 12:e0135023. doi: 10.1128/aac.01350.
    PubMed     Abstract available
    
    
    
25. MIAH M, Davis AM, Hannoun C, Said JS, et al
    Identification of epidermal growth factor receptor-tyrosine kinase inhibitor targeting the VP1 pocket of human rhinovirus.
    Antimicrob Agents Chemother. 2024;68:e0106423.
    PubMed     Abstract available
    
    
    
26. ZHANG R, Zhou J, Yan H, Liu X, et al
    Manidipine is not a potential inhibitor against SARS-CoV-2 main protease.
    Antimicrob Agents Chemother. 2024;68:e0129723.
    PubMed    
    
    
    February 2024
27. PLOTNIK D, Sager JE, Aryal M, Fanget MC, et al
    A phase 1 study in healthy volunteers to investigate the safety, tolerability, and pharmacokinetics of VIR-2482: a monoclonal antibody for the prevention of severe influenza A illness.
    Antimicrob Agents Chemother. 2024 Feb 20:e0127323. doi: 10.1128/aac.01273.
    PubMed     Abstract available
    
    
    January 2024
28. YANG H, Yu X, Hou W, Liu X, et al
    Effectiveness and safety of nirmatrelvir-ritonavir in kidney transplant recipients with severe kidney dysfunction infected with COVID-19.
    Antimicrob Agents Chemother. 2024 Jan 30:e0138423. doi: 10.1128/aac.01384.
    PubMed     Abstract available
    
    
    
29. BAKER J, Ombredane H, Daly L, Knowles I, et al
    Pan-antiviral effects of a PIKfyve inhibitor on respiratory virus infection in human nasal epithelium and mice.
    Antimicrob Agents Chemother. 2024;68:e0105023.
    PubMed     Abstract available
    
    
    
30. STRIZKI JM, Gaspar JM, Howe JA, Hutchins B, et al
    Molnupiravir maintains antiviral activity against SARS-CoV-2 variants and exhibits a high barrier to the development of resistance.
    Antimicrob Agents Chemother. 2024;68:e0095323.
    PubMed     Abstract available
    
    
    December 2023
31. ZHANG H, Zhou J, Chen H, Mao J, et al
    Phase I study, and dosing regimen selection for a pivotal COVID-19 trial of GST-HG171.
    Antimicrob Agents Chemother. 2023 Dec 15:e0111523. doi: 10.1128/aac.01115.
    PubMed     Abstract available
    
    
    November 2023
32. TONG X, Keung W, Arnold LD, Stevens LJ, et al
    Evaluation of in vitro antiviral activity of SARS-CoV-2 M(pro) inhibitor pomotrelvir and cross-resistance to nirmatrelvir resistance substitutions.
    Antimicrob Agents Chemother. 2023;67:e0084023.
    PubMed     Abstract available
    
    
    July 2023
33. PALOMINO-CABRERA R, Tejerina F, Molero-Salinas A, Ferris M, et al
    Frequent Emergence of Resistance Mutations Following Complex Intra-Host Genomic Dynamics in SARS-CoV-2 Patients Receiving Sotrovimab.
    Antimicrob Agents Chemother. 2023;67:e0026623.
    PubMed     Abstract available
    
    
    April 2023
34. DE LEON P, Canas-Arranz R, Bustos MJ, Saiz M, et al
    Inhibition of Human Coronaviruses by Combinations of Host-Targeted and Direct-Acting Antivirals.
    Antimicrob Agents Chemother. 2023;67:e0170322.
    PubMed     Abstract available
    
    
    March 2023
35. ZHANG D, Zhao Y, You X, He S, et al
    Repurposing Axl Kinase Inhibitors for the Treatment of Respiratory Syncytial Virus Infection.
    Antimicrob Agents Chemother. 2023;67:e0148722.
    PubMed     Abstract available
    
    
    
36. LIU STH, Mirceta M, Lin G, Anderson DM, et al
    Safety, Tolerability, and Pharmacokinetics of Anti-SARS-CoV-2 Immunoglobulin Intravenous (Human) Investigational Product (COVID-HIGIV) in Healthy Adults: a Randomized, Controlled, Double-Blinded, Phase 1 Study.
    Antimicrob Agents Chemother. 2023;67:e0151422.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Influenza is free of charge.